This is a snippet of the transcript, sign up to read more.
It varies depending on the market data you're looking at. Generally, the combined category of spirits and RTD is significantly larger. However, spirits alone have seen substantial growth in value over the years, contributing significantly to the overall business growth. Beer accounts for $7 billion, wine for $5.1 billion, spirits for $5.3 billion, and ready-to-drink products for$ 4 billion. These figures are in billions of dollars. In terms of volume, ready-to-drink products account for 279 million liters, wine for about 320 million liters, and beer for one billion liters. So, beer still holds the largest share of overall sales within Australia, both in terms of volume and value.
This is a snippet of the transcript, sign up to read more.
In the early stages, we only had tonic, and so it was really just about gin and tonic. Fever-Tree then introduced sodas to match up with a Paloma in tequila or a rum and soda that they had produced, which kind of diverted away from their core business. This happened quite quickly. I think they realized that there was initially going to be a downturn in tonic sales because the gin sales were growing and were going to reach capacity. Then gingers kind of came in with ginger beer and ginger ale and spicy this and clementine and all these other things that kind of came in at a rush. But ultimately, my point to you before about the share of a mix of sales was 95% tonics., people still just wanted to talk about gin and tonic in Australia. With ginger beer and ginger ale, Schweppes ginger ale and Bundaberg ginger beer have never put a foot wrong. They are great products and very entrenched in the way of life here. So that's a much harder area.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.